• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.13% Nasdaq Up0.70%

    ImmunoGen, Inc. (IMGN)

    -NasdaqGS
    5.93 Up 0.03(0.51%) 4:00PM EST
    |After Hours : 5.97 Up 0.04 (0.67%) 4:50PM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    ImmunoGen, Inc.
    830 Winter Street
    Waltham, MA 02451
    United States - Map
    Phone: 781-895-0600
    Fax: 781-895-0611
    Website: http://www.immunogen.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:307

    Business Summary 

    ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates include IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia. The company also develops compounds, such as AMG 172 that is in Phase I clinical trials for the treatment of clear cell renal cell carcinoma; AMG 595, which is in Phase I clinical trials for treating glioblastoma; BAY 94-9343 is in early clinical trials for the treatment of mesothelioma and ovarian cancer; BT-062 for multiple myeloma; SAR3419, which has completed Phase II clinical trials for the treatment of diffuse large B-cell lymphoma; SAR650984 that is in early clinical trials for the treatment of multiple myeloma; SAR566658 that is in Phase I clinical trials for treating CA6-positive solid tumors; and SAR408701 for solid tumors. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; the Roche Group; and Sanofi. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on ImmunoGen, Inc.

    Corporate Governance 
    ImmunoGen, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 4. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 4; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Daniel M. Junius , 62
    Chief Exec. Officer, Pres and Director
    863.00K1.12M
    Mr. David B. Johnston , 59
    Chief Financial Officer and Exec. VP
    314.00K0.00
    Dr. John M. Lambert Ph.D., 63
    Chief Scientific Officer and Exec. VP of Research
    528.00K349.00K
    Dr. Charles Q. Morris MB ChB, MRCP, 49
    Chief Devel. Officer and Exec. VP
    609.00K144.00K
    Ms. Carol Hausner ,
    Exec. Director of Investor Relations & Corp. Communications
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders